Cutaneous vascular conductance (CVC) increases in response to local skin heating. While attenuation of vasoconstrictor responsiveness due to local heating has been demonstrated, the mechanism(s) responsible for this attenuation remain unclear. Nitric oxide has been shown to at least partially contribute to this response, but other mechanisms also may be involved. The purpose of this study was to test the hypothesis that local heating diminishes cutaneous vasoconstrictor responsiveness through a nitric oxide independent mechanism by altering postsynaptic reactivity to norepinephrine. A follow-up protocol tested the hypothesis that local heating attenuates the pre-synaptic release of neurotransmitters that cause vasoconstriction, also via non-nitric oxide mechanisms. Protocol I: in 8 subjects, CVC was assessed while increasing doses of norepinephrine (via intradermal microdialysis) were administered at adjacent sites separately heated to 34 and 40 °C. Protocol II: in an identical but separate protocol, in 7 subjects, CVC was assessed while increasing doses of tyramine, which causes release of neurotransmitters from adrenergic nerves, were administered. At each site for both protocols, nitric oxide synthesis was inhibited (via microdialysis administration of N G -nitro-L-arginine methyl ester) and flow was matched (via microdialysis administration of adenosine), leaving temperature as the only variable different between sites. For both protocols, non-linear regression analysis revealed no difference (P > 0.05) in the effective drug concentration causing 50% of the vasoconstrictor response. Minimum CVC (protocol I, mean ± SD: 6.3 ± 2.0 and 9.0 ± 4.0 %CVC peak ; protocol II: 19.3 ± 9.3 and 20.5 ± 11.9 %CVC peak at the 34 and 40 °C sites, respectively) was not different between sites. Independent of nitric oxide, local skin heating to 40 °C does not attenuate adrenergically-mediated cutaneous vasoconstriction through pre-or post-synaptic mechanisms.
INTRODUCTION
In humans, heat stress increases cutaneous vascular conductance (CVC) as a result of withdrawal of vasoconstrictor neural activity, engagement of a sympathetic active vasodilator system, and direct effects of increased local temperature (12) . Increased local temperature can occur in conditions in which ambient temperature surpasses skin temperature, and/or high humidity conditions in which sweating becomes less efficient in removing heat from the skin (19) .
During pronounced heat stress, cardiac output can increase upwards to 7 l/min over resting baseline, with the potential for 50% or more of total cardiac output being distributed to the skin (22, 23) . This elevated CVC can present a challenge to blood pressure regulation, especially if orthostasis is combined with heat stress (15, 30) . The precise mechanism by which heat stress impairs orthostatic tolerance is incompletely understood, but it may be related to increased local skin temperature since local heating attenuates cutaneous vasoconstriction elicited by lower body negative pressure (16) , at the onset of exercise (26), and during administration of exogenous norepinephrine (29) . Consistent with human data, elevated local temperature reduces adrenergic responsiveness in isolated canine vessel preparations (4, 28) .
It is unclear how local heating interferes with cutaneous vasoconstriction. Cutaneous vasodilation during sustained local heating is primarily nitric oxide dependent (13, 17) , and nitric oxide has been shown to attenuate cutaneous vasoconstrictor responsiveness (6, 11, 24, 25, 33) , but it is unclear if nitric oxide is solely responsible for diminished cutaneous vasoconstriction associated with local heating. Non-nitric oxide mechanisms, such as differences in skin blood flow between locally heated and non-heated sites (29) and differences in temperature per se (16) may contribute to local heating attenuation of cutaneous vasoconstriction.
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The purpose of this study was to test the hypothesis that elevated temperature itself attenuates cutaneous vasoconstrictor responsiveness, through pre-and post-synaptic mechanisms, when nitric oxide and baseline skin blood flow are controlled.
METHODS

Subjects
Subjects were free of any known cardiovascular, metabolic, or neurological diseases.
Eight individuals (4 women and 4 men) participated in protocol I and seven individuals (3 women and 4 men) participated in protocol II. Their mean ± SD age, height and weight were 38 ± 10 y, 172.0 ± 8.8 cm, 77.9 ± 16.2 kg and 38 ± 13 y, 178.5 ± 6.2 cm, and 77.5 ± 12.0 kg for protocols I and II, respectively. The phase of the menstrual cycle was not controlled for in this study. Study approval was given by the institutional review boards at the University of Texas Southwestern Medical Center at Dallas and at Presbyterian Hospital of Dallas, and subjects provided written informed consent prior to enrolling.
Instrumentation
For both protocols, subjects rested supine while microdialysis membranes (Bioanalytical Systems, West Lafayette, IN) were placed at 4 sites in posterior forearm skin. Each membrane was perfused with lactated Ringer's solution (Baxter, Deerfield, IL) at a rate of 2 μl/min via a perfusion pump (Harvard Apparatus, Holliston, MA). On the skin above the membrane, each site was instrumented with a local heater (PF 450, Perimed, North Royalton, OH) covering approximately 7 cm 2 and a laser-Doppler flow probe (Model DP7a, Moor Instruments, Wilmington, DE) housed in the local heater to measure skin blood flow. A thermocouple (Type T, Omega Engineering, Stamford, CT) was placed between the skin and local heater to monitor local skin temperature. Arterial blood pressure was obtained intermittently using Local heating and vasoconstriction 3 electrosphygmomanometry of the brachial artery (Tango, SunTech Medical Instruments, Raleigh, NC).
Procedures for Protocol I
After instrumentation, sodium nitroprusside (SNP) was administered for approximately 15 -20 min through the microdialysis membranes to elicit peak cutaneous vasodilation at each site. Following SNP administration, membranes were perfused with lactated Ringer's solution for approximately 2 -2.5 hours while skin blood flow returned to pre-SNP baseline levels. The first few subjects received 50 mM SNP to elicit peak cutaneous vasodilation, but this dose required an inordinately long time for skin blood flow to return to baseline following cessation of SNP administration. Consequently, subsequent subjects received 28 mM SNP to elicit peak cutaneous vasodilation, while reducing the time required for skin blood flow to return to baseline. This latter concentration of SNP has been shown to cause maximal vasodilation in the cutaneous vasculature (13, 18, 31) . The nitric oxide synthase inhibitor, N G -nitro-L-arginine methyl ester (L-NAME; 10 mM), was then administered at all sites. This concentration of L-NAME has been shown to inhibit nitric oxide synthase to the same extent as higher doses (18) .
Two sites were then locally heated to 34 °C and the other two sites were locally heated to 40 °C, while L-NAME continued to be perfused through all sites. When CVC at 34 °C and 40 °C sites were closely matched (within ~ 10 %CVC peak units) across all 4 sites, data from the two 34 °C sites were averaged and compared with data averaged from the two 40 °C sites. Otherwise, data from the site locally heated to 34 °C that most closely matched CVC from the site locally heated to 40 °C (within ~ 10 %CVC peak units) were selected for analysis. Once skin blood flow was stable at all sites, a combination of 5.6 mM adenosine and 10 mM L-NAME was perfused through all membranes to match skin blood flow, by nitric oxide independent mechanisms, Local heating and vasoconstriction between sites at 34 °C and those at 40 °C. Once skin blood flow stabilized, progressively increasing doses of norepinephrine (from 1 × 10 -8 M to 1 × 10 -2 M in 1 × 10 -1 M increments) were administered. Upon the new dose passing through the "dead space" of the microdialysis probe, thereby ensuring that the new dose was at the membrane, each dose of norepinephrine was administered for 5 min at a perfusion rate of 2 μl/min. Throughout norepinephrine administration, sites continued to receive the combination of 5.6 mM adenosine and 10 mM L-NAME.
Procedures for Protocol II
Given the findings from protocol I, a follow-up protocol was conducted to determine if local heating altered vasoconstrictor responsiveness via a pre-synaptic mechanism. The procedures for protocol II were identical to protocol I with the following exceptions. After sites were locally heated, a combination of 5.6 mM adenosine and 10 mM L-NAME was perfused through the sites locally heated at 34 °C while a slightly lower concentration of adenosine (2.8 mM) and 10 mM L-NAME was perfused through the sites locally heated at 40 °C, thus improving the matching of CVC between sites relative to protocol I. Like in protocol I, if CVCs at both 34 °C sites were within 10 %CVC peak units of CVCs at the 40 °C sites, then CVCs for the respective temperature sites were averaged and these averaged values were statistically evaluated. If this was not the case then CVC at the 34 °C site that most closely matched CVC at the 40 °C site (also within ~ 10 %CVC peak units) were statistically compared. After skin blood flow stabilized, progressively increasing doses of tyramine (1 × 10 -7 M to 1 × 10 -2 M in 1 × 10 -1 M increments) were administered to all sites for 6 min per dose at a perfusion rate of 2 μl/min to cause the release of neurotransmitters, including norepinephrine, from sympathetic adrenergic Local heating and vasoconstriction 5 nerve endings. Like in protocol I, sites continued to receive both adenosine and 10 mM L-NAME throughout tyramine administration.
Data Analysis
Data from both protocols were analyzed similarly, so the following pertains to the entire data set. Data were acquired continuously at a sampling rate of 50 Hz using a data acquisition system (Biopac, Santa Barbara, CA). Data from the final minute of each dose of drug were averaged and analyzed. CVC was calculated as the ratio of arbitrary skin blood flux units to mean arterial pressure and normalized to responses achieved during peak cutaneous vasodilation via SNP administration (%CVC peak ). In protocol I, data were collected from 11 subjects, but data from 3 individuals were excluded for the following reasons: two of these subjects had CVCs at 34 °C and 40 °C sites that differed by more than 15 %CVC peak units and the third subject did not respond to norepinephrine, probably because of a failure of the microdialysis membrane. In protocol II, 8 subjects completed the study, but 1 subject was excluded because of failure to respond to tyramine. CVC data were mathematically modeled using non-linear regression curve fitting (Prism, GraphPad, San Diego, CA), and dose-response curves for %CVC peak were generated. The model identified the effective drug concentration causing 50% of the maximal vasoconstrictor response (EC 50 ), as well as the lowest %CVC peak values achieved during drug administration. Data from each site (34 °C vs. 40 °C) derived from the model were then compared using paired samples t-tests. Additional data analysis included a two-way repeated measures ANOVA (site × dose) to compare local skin temperature between sites across drug doses as well as %CVC peak at each site for each dose of the respective drug. Data are expressed as means ± SD. A P-value less than 0.05 was considered statistically significant.
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RESULTS
Procotol I
Local heating elicited average skin temperatures of 34.31 ± 0.31 °C and 39.72 ± 0.55 °C at the 34 °C and 40 °C sites, respectively, across all drug doses (main effect of site, P < 0.001).
Administration of adenosine was moderately successful in matching %CVC peak between sites prior to norepinephrine administration (44.2 ± 18.0% and 51.4 ± 21.0% for the 34 °C and 40 °C sites, respectively, P = 0.054). Non-linear regression curve fitting for the norepinephrine dose response had high goodness of fit at both the 34 °C (mean R 2 = 0.99 ± 0.01) and 40 °C (mean R 2 = 0.98 ± 0.01) sites (P = 0.57 between sites; Figure 1 ). There were no differences between sites (P > 0.05) for either of the parameters derived from the model [ Figure 1 ; EC 50 (log [M]) = -5.2 ± 0.7 and -4.7 ± 0.5 at 34 °C and 40 °C, respectively, and lowest %CVC peak = 6.3 ± 2.0 and 9.0 ± 4.0 at 34 °C and 40 °C sites, respectively] indicating a given dose of norepinephrine caused a similar degree of vasoconstriction at each site. Likewise, the ANOVA assessing %CVC peak between sites across each dose of norepinephrine did not reveal a significant interaction (P = 0.09), thereby further indicating the thermal status of the site did not affect the responsiveness to norepinephrine.
Protocol II
Because of the absence of an effect of local temperature on post-synaptic vasoconstrictor responsiveness outlined in protocol I, protocol II was adopted to evaluate the hypothesis that elevated local temperature attenuates the release of neurotransmitters leading to cutaneous vasoconstriction. Skin temperature averaged 34.43 ± 0.33 °C at the 34 °C site and 39.96 ± 0.25 °C at the 40 °C site, and this difference was maintained across all doses of tyramine (main effect of site, P < 0.001). Like in protocol I, administration of adenosine was sufficient in matching Local heating and vasoconstriction 7 %CVC peak between sites prior to tyramine administration (39.0 ± 21.6% and 43.3 ± 24.1% for the 34 °C and 40 °C sites, respectively, P = 0.14). Goodness of fit from the non-linear regression model was high for each site (mean R 2 = 0.95 ± 0.05 and 0.92 ± 0.07 for the 34 °C and 40 °C sites, respectively, P = 0.46 between sites; Figure 2 ). Local heating did not alter the EC 50 for tyramine (-3.9 ± 0.5 log [M] and -3.6 ± 0.4 log [M] for the 34 °C and 40 °C sites, respectively, P = 0.11), nor were there differences between sites for the minimum %CVC peak derived from the model (19.3 ± 9.3 and 20.5 ± 11.9 %CVC peak for the 34 °C and 40 °C sites, respectively, P = 0.49). As with protocol I, there was no significant interaction between sites and dose of tyramine for %CVC peak (P = 0.41).
DISCUSSION
The purpose of this study was to identify whether local temperature per se, independent of nitric oxide and potential differences in skin blood flow, attenuates cutaneous vasoconstrictor responsiveness through post-synaptic inhibition of norepinephrine-mediated vasoconstriction and/or through altered pre-synaptic release of stored neurotransmitters responsible for vasoconstriction (i.e., norepinephrine and perhaps co-transmitters such as neuropeptide Y). This was accomplished by measuring cutaneous blood flow responses to exogenous norepinephrine (to assess post-synaptic inhibition of α adrenergic stimulation) and tyramine (given the results of protocol I, to assess possible attenuation of neurotransmitter release from adrenergic nerves) at sites locally heated to differing temperatures while skin blood flow between sites was matched and nitric oxide synthase was inhibited. The primary finding from this study is that local heating to ~ 40 °C did not alter cutaneous vasoconstrictor responsiveness to exogenous norepinephrine in the absence of nitric oxide or differing baseline skin blood flows. Furthermore, pre-synaptic Local heating and vasoconstriction release of noradrenergic neurotransmitters was not impaired by local heating as evidenced by similar CVC responses to tyramine at 34 °C and 40 °C sites.
The lack of attenuation of cutaneous vasoconstrictor responsiveness at sites locally heated to 40 °C in the present study is in contrast to the findings from a previous study in which we reported that local heating to ≥ 37 °C attenuates cutaneous vasoconstrictor responsiveness to exogenous norepinephrine compared to a site maintained at 34 °C (29) . However, a primary limitation of that study, in contrast to the current study, was the absence of matched skin blood flow among sites heated from 34 °C to 42 °C. Thus, it may be that differences in skin blood flow between sites, not local temperature, was the primary mechanism resulting in attenuated vasoconstrictor responsiveness at the sites ≥ 37 °C relative to the control site at 34 °C. This line of thinking is consistent with the literature highlighting the importance of the initial baseline in evaluating vascular responses (11, 20) . For example, greater vasodilation, and hence, higher skin Another difference between the present study and that of Wilson et al. (29) is the absence of control for nitric oxide production between sites heated to differing temperatures. Since nitric oxide has been demonstrated to impair vasoconstriction in animal models (9, 10, 14, 33) , in human skeletal muscle (5) , and in human skin (6, 11, 24, 25) , attenuated cutaneous vasoconstriction between sites heated to different local temperatures in Wilson et al.'s study (29) may have been due to the influence of varying concentrations of nitric oxide.
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Nitric oxide may not be the most important component of local heating that attenuates cutaneous vasoconstriction as evidenced by data from Low et al. (16) . They compared the reduction in CVC to lower body negative pressure at sites with different local temperatures.
Four skin sites were initially heated to 34 °C for 15 min. Two control sites received lactated Ringer's solution while the other two sites received 10 mM L-NAME for 10 min. Then lower body negative pressure at 60 mm Hg was administered for 5 min. After a 5-min recovery, two of the sites were heated to 39 °C while the other two sites were heated to 42 °C. One site at each temperature received lactated Ringer's solution to serve as a control while the other site at each temperature that had received L-NAME during heating to 34 °C received adenosine combined with 10 mM L-NAME. Then lower body negative pressure at 60 mm Hg was administered for 5 min as before. The decrease in CVC during lower body negative pressure was smaller at the sites heated to 42 °C than at those heated to 39 °C, while the decrease in CVC at the 39 °C sites was similar to the decrease at those sites with temperature clamped at 34 °C. However, for a given local temperature (e.g., 39 °C or 42 °C), there were no differences in the magnitude of the decrease in CVC between sites that received L-NAME relative to sites that did not receive L-NAME. This observation suggests that nitric oxide may not be the primary mechanism impairing cutaneous vasoconstrictor responsiveness during local heating. Nevertheless, in 
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Studies focusing on cold-induced vasoconstriction may offer insight into the mechanisms behind the current findings. Since human and animal studies have shown reduced adrenergic transmitter release in conjunction with reduced local temperature (3, 7) , the potentiation of smooth muscle contraction responsible for vasoconstriction during local cooling has been attributed to alteration in location (1, 2, 27) and/or affinity of α 2 -adrenergic receptors (7) . The absence of differences in vasoconstrictor responsiveness between sites heated to 34 °C and 40 °C in the present study suggests that unlike local cooling, local heating does not reduce adrenergic transmitter release and/or does not interfere with the translocation or affinity of α 2 -adrenoceptors.
For the current study, local temperature was elevated to 40 °C, whereas local heating to 42 °C is commonly performed to elicit maximal cutaneous vasodilation. A local temperature of 40 °C was selected instead of 42 °C because of the inability to consistently match CVC at the 34 °C site with that achieved at a 42 °C site via non-nitric oxide mechanisms (i.e., with a coinfusion of L-NAME). Had 42 °C local heating been employed in the current study, CVC would have been substantially higher than CVC at the 34 °C site. We therefore cannot exclude the possibility that with local heating greater than 40 °C, cutaneous vasoconstrictor responsiveness is impaired due to temperature itself (i.e., independent of skin blood flow and nitric oxide).
Although there were no significant differences in %CVC peak between the sites (P = 0.054), %CVC peak prior to drug administration was 7 units higher at the site heated to 40 °C, which may be physiologically meaningful. Nevertheless, the minimum %CVC peak derived from the non-linear regression model, as well as the EC 50 values, were not different between sites.
This observation supports the conclusion of an absence of a reduction in vasoconstrictor responsiveness at the site heated to 40 °C, despite an elevated (albeit a non-statistically different) %CVC peak at this site prior to norepinephrine administration.
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Perspectives
It is recognized that encountering local skin temperatures of ~ 40 °C is unlikely under ordinary daily activities, except when environmental temperature is elevated in conjunction with high humid conditions or conditions in which evaporation of sweat is impeded or abolished [e.g., wearing nuclear, biological, and chemical protective suits]. The basis for evaluating such a high local skin temperature was to maximize the potential effect of elevated local temperature on cutaneous vasoconstrictor responsiveness. Since no effect was observed, it is unlikely that local skin temperatures, independent of skin blood flow and nitric oxide, below the applied level (i.e., in a more physiological range) attenuate cutaneous vasoconstrictor responsiveness.
Elevated skin temperature, albeit typically below 40 °C, commonly occurs in heat stress conditions. For example, in high ambient temperature environments, skin temperature can reach 37 °C or more (8, 21, 32) . This information, coupled with prior work suggesting that local heating attenuates cutaneous vasoconstrictor responsiveness (16, 25, 26, 29) , provides a possible mechanism by which orthostatic tolerance is reduced in heat-stressed individuals (15, 30) . The present data demonstrate that attenuated blood pressure control in subjects with elevated skin blood flow, secondary to local heating, is not because of elevated local temperature per se (at least at skin temperature ≤ 40 °C), but rather a yet to be identified effect of that elevated local temperature.
In summary, local heating of skin to 40 °C in the absence of nitric oxide and with matched skin blood flow had no effect on cutaneous vasoconstrictor responsiveness to exogenous norepinephrine administration compared to local clamping of skin temperature at 34 °C. Likewise, pre-synaptic release of neurotransmitters that cause vasoconstriction, stimulated by tyramine, also was not affected by local heating to 40 °C compared to 34 °C. Attenuation of cutaneous vasoconstrictor responsiveness associated with local heating is not because of an independent effect of elevated local temperature. Future studies are needed to investigate what mechanisms, occurring in conjunction with local heating, may be responsible for attenuated cutaneous vasoconstrictor responsiveness.
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FIGURE LEGENDS
